Accretion Pharmaceuticals Ltd. was incorporated on November 29, 2023. The company manufactures and markets a variety of pharmaceutical products, including tablets, capsules, ointments, and oral liquids. The company also offers contract manufacturing and loan licensing services to corporate clients.
| Bidding Dates |
|---|
| 14 May 2025 - 16 May 2025 |
| Subscription |
|---|
| 7.32x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹1,15,200 | 1 | 1 | 1200 | 2.9 M | ₹96 - ₹101 | 73.5 % | ₹282.8 M - ₹297.5 M | RHP DOC |
Accretion Pharmaceuticals IPO SUBSCRIPTION STATUS
16 May '25Accretion Pharmaceuticals IPO overall subscription rate was 7.32 times the total available shares
Accretion Pharmaceuticals IPO retail subscription rate was 13.47 times in the retail segment
Accretion Pharmaceuticals IPO non-institutional investor subscription rate was 13.14 times in the non-institutional investor category
Accretion Pharmaceuticals IPO Qualified Institutional Bidder subscription rate was 1.26 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
16 May 2025 (Day 3) | 13.47x | 13.14x | 1.26x |
15 May 2025 (Day 2) | 5.04x | 3.07x | 0.08x |
14 May 2025 (Day 1) | 2.32x | 1.5x | - |
Accretion Pharmaceuticals FINANCIALS
| Period | Net Profit (Rs in crore) | Revenue from Operations (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 9MFY25 | 5.2 | 35.7 | -0.7 | -2.1 | 24.7% |
| FY24 | 3.9 | 33.7 | -1.3 | -1.4 | 23.1% |
| FY23 | 0.1 | 29.4 | 0.3 | -0.8 | 7.3% |
| FY22 | 0.1 | 22.3 | 2.2 | 1.9 | 8.7% |
Accretion Pharmaceuticals IPO SUBSCRIPTION STATUS DETAILS
Accretion Pharmaceuticals had 2.9 M shares on offer
Accretion Pharmaceuticals IPO offer price was in the range ₹96 - ₹101
Accretion Pharmaceuticals IPO minimum Investment was ₹115200
Accretion Pharmaceuticals IPO issue size was ₹ 282.8 M - ₹ 297.5 M
Accretion Pharmaceuticals had a minimum lot size of 1200 Shares per application
Accretion Pharmaceuticals NUMBER OF SHARES ON OFFER
Accretion Pharmaceuticals IPO IMPORTANT DATES
| Issue Open Date | 14 May 2025 |
| Issue close Date | 16 May 2025 |
| Allotment Date | 19 May 2025 |
| Refund Date | 20 May 2025 |
| Demat Account Credit Date | 20 May 2025 |
| Listing Date | 21 May 2025 |
| Listing on Exchange(s) | NSE |
| Accretion Pharmaceuticals Allotment Status | Exchange/ Registrar |
Accretion Pharmaceuticals IPO subscription opened on 14 May 2025, and closed on 16 May 2025
IPO allotment for Accretion Pharmaceuticals was finalized on Monday, 19 May 2025
IPO listing for Accretion Pharmaceuticals was on NSE on Wednesday, 21 May 2025
Accretion Pharmaceuticals IPO LISTING GAINS
| Issue Price (adjusted) | 101.0 |
| Listing Open Price | 79.0 |
| Listing Close Price | 83.0 |
| Listing Gain% | -21.8% |
| Current Gain% | 79.2% |
Accretion Pharmaceuticals Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accretion Pharmaceuticals Ltd. | 181 | 201.2 | 20.8 | 0.5 | 2.2 | 17.7 | 12.6 | 89.8 | 56.3 | 9.7 | 42.3 | 8.7 | 42.3 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Accretion Pharmaceuticals INFORMATION ON IPO ISSUE
About Accretion Pharmaceuticals
Accretion Pharmaceuticals Ltd. was incorporated on November 29, 2023. The company manufactures and markets a variety of pharmaceutical products, including tablets, capsules, ointments, and oral liquids. The company also offers contract manufacturing and loan licensing services to corporate clients.
Object of the Issue
- Capital expenditure towards the purchase of new equipment/machinery
- Capital expenditure towards the upgradation of an existing manufacturing facility
- Repayment/prepayment of certain borrowings availed by the company
- Funding working capital requirements
- General corporate purpose
Accretion Pharmaceuticals - PROMOTERS
| Name |
|---|
| Vivek Ashok Kumar Patel |
| Harshad Nanubhai Rathod |
| Mayur Popatlal Sojitra |
| Hardik Mukundbhai Prajapati |
Accretion Pharmaceuticals Book Running Lead Manager
Jawa Capital Services Private Limited
mbd@jawacapital.in
Accretion Pharmaceuticals Registrar to the issue
Kfin Technologies Limited
apl.ipo@kfintech.com
Accretion Pharmaceuticals Strengths
Product range
The company offers a wide variety of healthcare formulations, enabling it to serve a large customer base in both domestic and international markets. Its commitment to quality, competitive pricing, and continuous product expansion supports its reputation as a global manufacturer
Quality focus
The company prioritises delivering high-quality products by continuously improving its production processes. It holds ISO 9001:2015 and ISO 14001:2015 certifications, reflecting its commitment to quality and environmental standards, which helps attract both domestic and international customers
Strong relationships
The company maintains long-term relationships with clients and suppliers, backed by experienced leadership and a well-established supply chain. This has helped build goodwill and trust in the market
Accretion Pharmaceuticals Risks
Export dependence
The company earns a major part of its revenue from exports, making it sensitive to global factors such as currency fluctuations, trade policies, and geopolitical risks. Any decline in export profitability, without offsetting growth in domestic sales, can reduce profit margins, affect reinvestment plans, and weaken long-term financial stability
Regulatory risk
The pharmaceutical sector is highly regulated, and the company must comply with multiple environmental, safety, and health laws. Non-compliance or delays in obtaining or renewing statutory licenses and approvals may result in fines, legal action, or shutdowns
Manufacturing risk
The company operates with a single manufacturing facility in Ahmedabad, Gujarat. Any disruption, such as machinery breakdown, power failure, natural disasters, or social unrest, could severely impact operations. A prolonged shutdown, labor disputes, or failure to comply with regulatory approvals may result in financial losses
IPO FAQs
The promoters of the company are Vivek Ashok Kumar Patel, Harshad Nanubhai Rathod, Mayur Popatlal Sojitra and Hardik Mukundbhai Prajapati.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 96.0 - 101.0.
The IPO application opens on May 14, 2025 and closes on May 16, 2025.
The minimum lot size for the IPO is 1200. The maximum lot size for the IPO is 1200.
For all category investors, the minimum application amount for this IPO is Rs. 115,200.0, the maximum value for this IPO is Rs 121,200.0.
This IPO will be allotted on May 19, 2025.
The refund will be credited to your account on May 20, 2025.
The allotted shares will be credited to your demat on May 20, 2025.
Accretion Pharmaceuticals Ltd.’s shares listed on the stock exchanges on May 21, 2025.